Tumor-associated macrophages in stage IIIA pN2 non-small cell lung cancer after neoadjuvant chemotherapy and surgery

Po Hao Feng, Chih Teng Yu, Chin Yang Wu, Meng Jung Lee, Wei Hwa Lee, Liang Shun Wang, Shu Min Lin, Jen Fen Fu, Kang Yun Lee, Tzung Hai Yen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: Most of the patients with stage IIIA pN2 non-small cell lung cancer (NSCLC) develop recurrence after surgery. It is not clear whether post neoadjuvant chemotherapy tumor-associated macrophages is associated with recurrence. Patients and Methods: Stage IIIA pN2 NSCLC patients underwent cisplatin/docetaxel neoadjuvant chemotherapy and surgery were retrospectively enrolled. Immunohistochemical staining of CD68 was used to identify macrophages in surgical resected stored tissues. Results: The objective response rate of cisplatin/docetaxel was 68%, overall median disease-free survival (DFS) was 13.1 months and median overall survival (OS) 36.8. months. Multiple Cox regression analysis showed low total macrophage numbers and mediastinal lymph nodes downstaging were independent factors for longer DFS, whereas high islet/stromal macrophages ratio was an independent facto for OS. In patients downstaged to pN0, low total macrophage numbers was also associated with longer DFS. Conclusions: Low total macrophage number is an independent factor for better DFS in pN2 stage IIIA NSCLC patients receiving neoadjuvant chemotherapy and surgical resection, which association was kept in those downstaged to pN0. Further studies are warrant to confirm the predictive role of TAMs and their potential causative role in tumor recurrence.

Original languageEnglish
Pages (from-to)593-603
Number of pages11
JournalAmerican Journal of Translational Research
Volume6
Issue number5
Publication statusPublished - 2014

Fingerprint

Chemotherapy
Macrophages
Non-Small Cell Lung Carcinoma
Surgery
Tumors
Cells
docetaxel
Drug Therapy
Disease-Free Survival
Neoplasms
Recurrence
Cisplatin
Survival
Regression analysis
Lymph Nodes
Regression Analysis
Tissue
Staining and Labeling

Keywords

  • Immunochemistry
  • Immunology
  • Lung cancer biology

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Tumor-associated macrophages in stage IIIA pN2 non-small cell lung cancer after neoadjuvant chemotherapy and surgery. / Feng, Po Hao; Yu, Chih Teng; Wu, Chin Yang; Lee, Meng Jung; Lee, Wei Hwa; Wang, Liang Shun; Lin, Shu Min; Fu, Jen Fen; Lee, Kang Yun; Yen, Tzung Hai.

In: American Journal of Translational Research, Vol. 6, No. 5, 2014, p. 593-603.

Research output: Contribution to journalArticle

Feng, Po Hao ; Yu, Chih Teng ; Wu, Chin Yang ; Lee, Meng Jung ; Lee, Wei Hwa ; Wang, Liang Shun ; Lin, Shu Min ; Fu, Jen Fen ; Lee, Kang Yun ; Yen, Tzung Hai. / Tumor-associated macrophages in stage IIIA pN2 non-small cell lung cancer after neoadjuvant chemotherapy and surgery. In: American Journal of Translational Research. 2014 ; Vol. 6, No. 5. pp. 593-603.
@article{e9b5a251f29347a8b49004737b0bcdb8,
title = "Tumor-associated macrophages in stage IIIA pN2 non-small cell lung cancer after neoadjuvant chemotherapy and surgery",
abstract = "Purpose: Most of the patients with stage IIIA pN2 non-small cell lung cancer (NSCLC) develop recurrence after surgery. It is not clear whether post neoadjuvant chemotherapy tumor-associated macrophages is associated with recurrence. Patients and Methods: Stage IIIA pN2 NSCLC patients underwent cisplatin/docetaxel neoadjuvant chemotherapy and surgery were retrospectively enrolled. Immunohistochemical staining of CD68 was used to identify macrophages in surgical resected stored tissues. Results: The objective response rate of cisplatin/docetaxel was 68{\%}, overall median disease-free survival (DFS) was 13.1 months and median overall survival (OS) 36.8. months. Multiple Cox regression analysis showed low total macrophage numbers and mediastinal lymph nodes downstaging were independent factors for longer DFS, whereas high islet/stromal macrophages ratio was an independent facto for OS. In patients downstaged to pN0, low total macrophage numbers was also associated with longer DFS. Conclusions: Low total macrophage number is an independent factor for better DFS in pN2 stage IIIA NSCLC patients receiving neoadjuvant chemotherapy and surgical resection, which association was kept in those downstaged to pN0. Further studies are warrant to confirm the predictive role of TAMs and their potential causative role in tumor recurrence.",
keywords = "Immunochemistry, Immunology, Lung cancer biology",
author = "Feng, {Po Hao} and Yu, {Chih Teng} and Wu, {Chin Yang} and Lee, {Meng Jung} and Lee, {Wei Hwa} and Wang, {Liang Shun} and Lin, {Shu Min} and Fu, {Jen Fen} and Lee, {Kang Yun} and Yen, {Tzung Hai}",
year = "2014",
language = "English",
volume = "6",
pages = "593--603",
journal = "American Journal of Translational Research",
issn = "1943-8141",
publisher = "e-Century Publishing Corporation",
number = "5",

}

TY - JOUR

T1 - Tumor-associated macrophages in stage IIIA pN2 non-small cell lung cancer after neoadjuvant chemotherapy and surgery

AU - Feng, Po Hao

AU - Yu, Chih Teng

AU - Wu, Chin Yang

AU - Lee, Meng Jung

AU - Lee, Wei Hwa

AU - Wang, Liang Shun

AU - Lin, Shu Min

AU - Fu, Jen Fen

AU - Lee, Kang Yun

AU - Yen, Tzung Hai

PY - 2014

Y1 - 2014

N2 - Purpose: Most of the patients with stage IIIA pN2 non-small cell lung cancer (NSCLC) develop recurrence after surgery. It is not clear whether post neoadjuvant chemotherapy tumor-associated macrophages is associated with recurrence. Patients and Methods: Stage IIIA pN2 NSCLC patients underwent cisplatin/docetaxel neoadjuvant chemotherapy and surgery were retrospectively enrolled. Immunohistochemical staining of CD68 was used to identify macrophages in surgical resected stored tissues. Results: The objective response rate of cisplatin/docetaxel was 68%, overall median disease-free survival (DFS) was 13.1 months and median overall survival (OS) 36.8. months. Multiple Cox regression analysis showed low total macrophage numbers and mediastinal lymph nodes downstaging were independent factors for longer DFS, whereas high islet/stromal macrophages ratio was an independent facto for OS. In patients downstaged to pN0, low total macrophage numbers was also associated with longer DFS. Conclusions: Low total macrophage number is an independent factor for better DFS in pN2 stage IIIA NSCLC patients receiving neoadjuvant chemotherapy and surgical resection, which association was kept in those downstaged to pN0. Further studies are warrant to confirm the predictive role of TAMs and their potential causative role in tumor recurrence.

AB - Purpose: Most of the patients with stage IIIA pN2 non-small cell lung cancer (NSCLC) develop recurrence after surgery. It is not clear whether post neoadjuvant chemotherapy tumor-associated macrophages is associated with recurrence. Patients and Methods: Stage IIIA pN2 NSCLC patients underwent cisplatin/docetaxel neoadjuvant chemotherapy and surgery were retrospectively enrolled. Immunohistochemical staining of CD68 was used to identify macrophages in surgical resected stored tissues. Results: The objective response rate of cisplatin/docetaxel was 68%, overall median disease-free survival (DFS) was 13.1 months and median overall survival (OS) 36.8. months. Multiple Cox regression analysis showed low total macrophage numbers and mediastinal lymph nodes downstaging were independent factors for longer DFS, whereas high islet/stromal macrophages ratio was an independent facto for OS. In patients downstaged to pN0, low total macrophage numbers was also associated with longer DFS. Conclusions: Low total macrophage number is an independent factor for better DFS in pN2 stage IIIA NSCLC patients receiving neoadjuvant chemotherapy and surgical resection, which association was kept in those downstaged to pN0. Further studies are warrant to confirm the predictive role of TAMs and their potential causative role in tumor recurrence.

KW - Immunochemistry

KW - Immunology

KW - Lung cancer biology

UR - http://www.scopus.com/inward/record.url?scp=84908070714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908070714&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84908070714

VL - 6

SP - 593

EP - 603

JO - American Journal of Translational Research

JF - American Journal of Translational Research

SN - 1943-8141

IS - 5

ER -